

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Substitute for form 1449/PTO			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			
(Use as many sheets as necessary)			
Sheet	1	of	2
		Attorney Docket Number	
		FERN-P006	

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	TESCH, GREG, et al., "Successes Achieved and Challenges Ahead in Translating Biomarkers into Clinical Applications", The AAPS Journal, Published online: 16 March 2010,	
		Retrieved from the web < <a href="http://www.aapsj.org/abstracts/abstr2000/am_year_abstr.asp">http://www.aapsj.org/abstracts/abstr2000/am_year_abstr.asp</a> >, American Association of Physical Scientists Arlington, Virginia/USA	
	2	RATNER, M.L., "Re-Emerges: Can a Genomics Platform Model Work in Diagnostics?", StartUp (published online 02/01/10), full article reprinted online on	
		Medical Devices Today, < <a href="http://www.medicaldevicestoday.com/2010/03/decode-reemerges-can-a-genomics-platform-model-work-in-diagnostics-.html">http://www.medicaldevicestoday.com/2010/03/decode-reemerges-can-a-genomics-platform-model-work-in-diagnostics-.html</a> >	
		Published March 11, 2010, Accessed 3/28/2010 11:21 AM, F-D-C Reports, Inc. and Windhover Information Inc., Rockville, MD/USA	
	3	HAYES, RONALD L. "Translation of Neurological Biomarkers to Clinically Relevant Platforms", Neuroproteomics, Methods in Molecular Biology,	
		Andrew K. Ottens and Kevin K.W. Wang (eds.), vol. 566, Chapter 20. pp. 303-313, 2009-08-05, Humana Press, New York City, NY/USA	
	4	DRESSLER, L.G., et al., "How Will GINA Influence Participation in Pharmacogenomics Research and Clinical Testing?"	
		Clinical pharmacology & Therapeutics, November 2009, pages 472-475, Volume 86, Number 5, Nature Publishing Group, International Offices.	
	5	BREGMAN-ESCHET, YAEL, "Genetic Databases And Biobanks: Who Controls Our Genetic Privacy?", SANTA CLARA COMPUTER & HIGH TECH. L.J., November 2006,	

Examiner Signature	/Robert Rines/	Date Considered	09/27/2010
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

**Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.R./**